<DOC>
	<DOCNO>NCT00506857</DOCNO>
	<brief_summary>Objectives : 1 . To determine relative toxicity , engraftment potential , kinetics engraftment , degree chimerism disease control achieve combination fludarabine busulfan different dose level different dose schedule patient undergo allogeneic stem cell transplant ( SCT ) . 2 . Determine pharmacokinetics , toxicity intravenous busulfan give equal total dose level give four time daily , daily . 3 . In vivo determination fludarabine inhibitory effect DNA repair .</brief_summary>
	<brief_title>Phase I/II Trial Fludarabine Plus Busulfan Allogeneic Progenitor Cell Support</brief_title>
	<detailed_description>Treatment : Participants blood test bone marrow test well test check lung , heart , kidney , liver function . Participants receive busulfan vein 2 4 day depend age medical condition . All participant receive fludarabine give 4 day . Participants undergo unmatched match unrelated donor receive ATG 4 day help engraftment donor progenitor cell . All drug give vein daily . The donor blood cell take donor process know apheresis . This occur donor receive 2 day granulocyte colony stimulate factor ( G-CSF ) increase her/his white cell count . The G-CSF also increase number immature ( stem cell ) collect . Apheresis similar platelet donation , white cell stem cell collect instead . About 3 5 apheresis procedure need get enough cell infusion . If apheresis use , donor bone marrow take general anesthesia . After participant receives donor stem cell , stem cell divide reconstitute bone marrow function , blood function , immunity . The donor stem cell give chemotherapy shorten period low blood count . They also give time achieve antileukemic effect whereby donor immune cell recognize participant 's leukemia `` foreign '' prevent recurrence . A small amount donor cell keep infusion future date ( usually 3 6 month post transplant ) try prevent disease come back . During 4 8 week follow blood cell infusion , participant need frequent blood test monitor count blood chemistry . Participants need frequent blood transfusion may admit hospital receive antibiotic develop fever . Bone marrow examine frequently begin four week treatment check response . Participants achieve normal bone marrow blood count evaluate determine appropriate form future therapy . Participants fail respond treatment offer therapy . This investigational study . All drug commercially available . Up 140 participant take part study . All enrol UT MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Less physiologic 75 year age . 2 . Interferon resistant late chronic phase CML eligible protocol high priority . 3 . Accelerated/Blastic Phase CML . 4 . Acute leukemia Intermediate High Risk MDS accord IPPS . 5 . Any Lymphoma Myeloma beyond CR1 ineligible protocol high priority . 6 . Patients must HLA compatible donor willing donate either peripheral blood bone marrow progenitor cell . 7 . Both patient donor must sign write informed consent . 1 . Uncontrolled infection 2 . Bilirubin &gt; 3.0 3 . Creatinine &gt; 2.5 4 . Performance Status &gt; Zubrod 2</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Leukemia</keyword>
	<keyword>MDS</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludara</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Progenitor Cell Transplantation</keyword>
	<keyword>Granulocyte colony stimulate factor</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Apheresis</keyword>
	<keyword>Blood cell infusion</keyword>
</DOC>